Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials

Susan L McElroy, James Hudson, M Celeste Ferreira-Cornwell, Jana Radewonuk, Timothy Whitaker, Maria Gasior, Susan L McElroy, James Hudson, M Celeste Ferreira-Cornwell, Jana Radewonuk, Timothy Whitaker, Maria Gasior

Abstract

The efficacy and safety of lisdexamfetamine dimesylate (LDX) vs placebo in binge eating disorder (BED) was evaluated in two multicenter, double-blind, placebo-controlled trials. Adults (study 1, n=383; study 2, n=390) meeting DSM-IV-TR BED criteria were randomized (1:1) to placebo or LDX (50 or 70 mg/day) dose titration; optimized doses were maintained to the end of double-blind treatment (week 12/early termination). Change from baseline in binge eating days/week at weeks 11-12 (primary efficacy endpoint) was assessed with mixed-effects models for repeated measures. Secondary endpoints related to binge eating and medical parameters, safety, and treatment compliance were also assessed. Least squares mean (95% CI) treatment differences for change from baseline binge eating days/week at weeks 11-12 significantly favored LDX (study 1: -1.35 [-1.70, -1.01]; study 2: -1.66 [-2.04, -1.28]; both P<0.001). In both studies, treatment-emergent adverse events (TEAEs) reported by ⩾10% of LDX participants were dry mouth, insomnia, and headache. Serious TEAEs occurred in two (1.1%) placebo participants in each study and in three (1.6%) and one (0.6%) LDX participants in study 1 and study 2, respectively. Across studies, mean increases from baseline at week 12/early termination with LDX for pulse and systolic and diastolic blood pressure ranged from 4.41-6.31 b.p.m. and 0.2-1.45 and 1.06-1.83 mm Hg, respectively. LDX (50 and 70 mg/day) was superior to placebo in decreasing binge eating days/week from baseline and improving binge eating-related key secondary endpoints. Safety results appear consistent with the known safety profile of LDX.

Figures

Figure 1
Figure 1
Study timeline and titration schedule (a) and participant disposition (b).
Figure 2
Figure 2
Change from baseline in binge eating days per week in Study 1 (a) and Study 2 (b), full analysis set. LDX, lisdexamfetamine dimesylate.

References

    1. Adler LA, Goodman DW, Kollins SH, Weisler RH, Krishnan S, Zhang Y et al (2008). Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 69: 1364–1373.
    1. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text Revision. American Psychiatric Association: Washington, DC.
    1. American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders, 5th edn. American Psychiatric Association: Washington, DC.
    1. Appolinario JC, Bacaltchuk J, Sichieri R, Claudino AM, Godoy-Matos A, Morgan C et al (2003). A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Arch Gen Psychiatry 60: 1109–1116.
    1. Arif H, Buchsbaum R, Weintraub D, Pierro J, Resor SR Jr, Hirsch LJ (2009). Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. Epilepsy Behav 14: 202–209.
    1. Claudino AM, de Oliveira IR, Appolinario JC, Cordas TA, Duchesne M, Sichieri R et al (2007). Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry 68: 1324–1332.
    1. Corwin RL, Boan J, Peters KF, Ulbrecht JS (2012). Baclofen reduces binge eating in a double-blind, placebo-controlled, crossover study. Behav Pharmacol 23: 616–625.
    1. Fairburn CG, Beglin SJ (1994). Assessment of eating disorders: interview or self-report questionnaire? Int J Eat Disord 16: 363–370.
    1. First M, Williams J, Spitzer R, Gibbon M (2007) Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Clinical Trials Version (SCID-CT). Biometrics Research, New York State Psychiatric Institute: New York, NY, USA.
    1. Golay A, Laurent-Jaccard A, Habicht F, Gachoud JP, Chabloz M, Kammer A et al (2005). Effect of orlistat in obese patients with binge eating disorder. Obes Res 13: 1701–1708.
    1. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL et al (1989). The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46: 1006–1011.
    1. Grilo CM, Masheb RM, Salant SL (2005). Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry 57: 1193–1201.
    1. Grilo CM, White MA (2013). Orlistat with behavioral weight loss for obesity with versus without binge eating disorder: randomized placebo-controlled trial at a community mental health center serving educationally and economically disadvantaged Latino/as. Behav Res Ther 51: 167–175.
    1. Guy W (1976) Clinical Global Impressions ECDEU Assessment Manual for Psychopharmacology, US Department of Health, Education, and Welfare; Public Health Service Alcohol, Drug Abuse and Mental Health Administration; NIMH Psychopharmacology Research Branch: Rockville, MD, pp 218–222.
    1. Hudson JI, Hiripi E, Pope HG Jr, Kessler RC (2007). The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 61: 348–358.
    1. Hudson JI, Lalonde JK, Coit CE, Tsuang MT, McElroy SL, Crow SJ et al (2010). Longitudinal study of the diagnosis of components of the metabolic syndrome in individuals with binge-eating disorder. Am J Clin Nutr 91: 1568–1573.
    1. Kessler RC, Berglund PA, Chiu WT, Deitz AC, Hudson JI, Shahly V et al (2013). The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys. Biol Psychiatry 73: 904–914.
    1. Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT et al (2012). The prevention and treatment of missing data in clinical trials. N Engl J Med 367: 1355–1360.
    1. Masheb RM, Grilo CM (2004). Quality of life in patients with binge eating disorder. Eat Weight Disord 9: 194–199.
    1. McElroy SL, Arnold LM, Shapira NA, Keck PE Jr, Rosenthal NR, Karim MR et al (2003). Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 160: 255–261.
    1. McElroy SL, Guerdjikova A, Kotwal R, Welge JA, Nelson EB, Lake KA et al (2007. a). Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry 68: 390–398.
    1. McElroy SL, Hudson JI, Capece JA, Beyers K, Fisher AC, Rosenthal NR et al (2007. b). Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry 61: 1039–1048.
    1. McElroy SL, Hudson JI, Mitchell JE, Wilfley D, Ferreira-Cornwell MC, Gao J et al (2015). Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry 72: 235–246.
    1. McElroy SL, Kotwal R, Guerdjikova AI, Welge JA, Nelson EB, Lake KA et al (2006). Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry 67: 1897–1906.
    1. McGregor C, Srisurapanont M, Mitchell A, Longo MC, Cahill S, White JM (2008). Psychometric evaluation of the Amphetamine Cessation Symptom Assessment. J Subst Abuse Treat 34: 443–449.
    1. Pataky Z, Gasteyger C, Ziegler O, Rissanen A, Hanotin C, Golay A (2013). Efficacy of rimonabant in obese patients with binge eating disorder. Exp Clin Endocrinol Diabetes 121: 20–26.
    1. Pennick M (2010). Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat 6: 317–327.
    1. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA et al (2011). The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168: 1266–1277.
    1. Reas DL, Grilo CM (2014). Current and emerging drug treatments for binge eating disorder. Expert Opin Emerg Drugs 19: 99–142.
    1. Siddiqui O (2011). MMRM versus MI in dealing with missing data—a comparison based on 25 NDA data sets. J Biopharm Stat 21: 423–436.
    1. Striegel-Moore RH, Dohm FA, Wilfley DE, Pike KM, Bray NL, Kraemer HC et al (2004). Toward an understanding of health services use in women with binge eating disorder. Obes Res 12: 799–806.
    1. Vocks S, Tuschen-Caffier B, Pietrowsky R, Rustenbach SJ, Kersting A, Herpertz S (2010). Meta-analysis of the effectiveness of psychological and pharmacological treatments for binge eating disorder. Int J Eat Disord 43: 205–217.
    1. Vyvanse (lisdexamfetamine dimesylate) (2015) Full Prescribing Information. Shire US Inc: Wayne, PA.
    1. Wigal T, Brams M, Gasior M, Gao J, Squires L, Giblin J et al (2010). Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct 6: 34.
    1. Wilfley DE, Crow SJ, Hudson JI, Mitchell JE, Berkowitz RI, Blakesley V et al (2008). Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. Am J Psychiatry 165: 51–58.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa